Investors in Eli Lilly have received a significant boost following a challenging start to the 2026 trading year. The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback